var data={"title":"Fluticasone (oral inhalation): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluticasone (oral inhalation): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7786?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluticasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluticasone (oral inhalation): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=fluticasone-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluticasone (oral inhalation): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349568\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ArmonAir RespiClick 113;</li>\n      <li>ArmonAir RespiClick 232;</li>\n      <li>ArmonAir RespiClick 55;</li>\n      <li>Arnuity Ellipta;</li>\n      <li>Flovent Diskus;</li>\n      <li>Flovent HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349569\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Arnuity Ellipta;</li>\n      <li>Flovent Diskus;</li>\n      <li>Flovent HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349572\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Inhalant (Oral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349626\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma: </b> Inhalation, oral: <b>Note:</b> Titrate to the lowest effective dose once asthma stability is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ArmonAir Respiclick (fluticasone propionate):</b> Dry powder inhaler: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">No prior treatment with inhaled corticosteroids: Initial: 55 mcg twice daily; maximum: 232 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prior treatment with inhaled corticosteroid: 55 mcg to 232 mcg twice daily (base starting dosage on strength of previous inhaled corticosteroid and disease severity); maximum: 232 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Arnuity Ellipta (fluticasone furoate):</b> Dry powder inhaler: Dosing based on previous asthma therapy: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">No prior treatment with inhaled corticosteroids: Initial: 100 mcg once daily; maximum: 200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prior treatment with inhaled corticosteroids: Initial: 100 to 200 mcg once daily; maximum: 200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flovent HFA (fluticasone propionate):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>US labeling:</i></b> <b>Note:</b> Dosing based on previous asthma therapy and asthma severity. May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metered dose inhaler: Initial (patients with no prior inhaled corticosteroids): 88 mcg twice daily; maximum: 880 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Canadian labeling:</i></b> <b>Note:</b> May increase dose after ~1 week of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metered dose inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild asthma: 100 to 250 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate asthma: 250 to 500 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe asthma: 500 mcg twice daily; may increase up to 1,000 mcg twice daily in very severe patients (eg, patients using oral corticosteroids [OCS]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007): HFA inhaler (refers to Flovent HFA 44 mcg, 110 mcg, and 220 mcg strengths available in US): <b>Note: </b>Administer in divided doses twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 88 to 264 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;264 to 440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma guidelines (GINA 2017): HFA inhaler (refers to Flovent HFA 50 mcg, 125 mcg, and 250 mcg strengths available in Canada):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 100 to 250 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;250 to 500 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;500 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flovent Diskus (fluticasone propionate):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>US labeling: </i></b> <b>Note:</b> Dosing based on previous asthma therapy and asthma severity. May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dry powder inhaler: Initial (patients with no prior inhaled corticosteroids): 100 mcg twice daily; maximum: 1,000 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Canadian labeling:</i></b> <b>Note:</b> May increase dose after ~1 week of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild asthma: 100 to 250 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate asthma: 250 to 500 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe asthma: 500 mcg twice daily; may increase up to 1,000 mcg twice daily in very severe patients (eg, patients using OCS).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007): Dry powder inhaler (refers to Flovent Diskus 50 mcg, 100 mcg, and 250 mcg strengths available in the US and Canada, and the 500 mcg strength available in Canada): <b>Note:</b> Administer in divided doses twice daily:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 100 to 300 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;300 to 500 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;500 mcg/day</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Global Initiative for Asthma guidelines (GINA 2017): Dry powder inhaler (refers to Flovent Diskus 50 mcg, 100 mcg, and 250 mcg strengths available in the US and Canada, and the 500 mcg strength available in Canada).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose: 100 to 250 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose: &gt;250 to 500 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose: &gt;500 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic obstructive pulmonary disease (stable) (off-label use): Inhalation, oral:</b> 50 to 500 mcg/day in combination with a long-acting bronchodilator (GOLD 2014; GOLD 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Eosinophilic esophagitis (off-label use): Oral (off-label route):</b> 440 to 880 mcg of aerosolized fluticasone swallowed (not inhaled) twice daily (880 to 1,760 mcg/day) (Alexander 2012; Butz 2014; Chuang 2015; Murali 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349625\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluticasone (oral inhalation): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Inhalation, oral: <b>Note: </b>Titrate to lowest effective dose once asthma stability achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ArmonAir Respiclick (fluticasone propionate):</b> Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Arnuity Ellipta (fluticasone furoate):</b> Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flovent HFA (fluticasone propionate):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>\n        <b>\n          <i>US labeling:</i></b></i> Metered dose inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to 11 years: 88 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>\n        <b>\n          <i>Canadian labeling: </i></b></i> Metered dose inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 1 to &lt;4 years: 100 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to &lt;16 years: 100 mcg twice daily. <b>Note:</b> Manufacturer labeling recommends Flovent HFA be administered as a minimum of 2 inhalations twice daily; therefore, patients requiring lower or higher dosages than 100 mcg twice daily should use Flovent Diskus.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;16 years and Adults: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007): HFA inhaler (refers to Flovent HFA 44 mcg, 110 mcg, and 220 mcg strengths available in US). <b>Note:</b> Administer in divided doses twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">0 to 4 years: 176 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to 11 years: 88 to 176 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;12 years: 88 to 264 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">0 to 4 years: &gt;176 to 352 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to 11 years: &gt;176 to 352 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;12 years: &gt;264 to 440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">0 to 4 years: &gt;352 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to 11 years: &gt;352 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;12 years: &gt;440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma guidelines (GINA 2017): HFA inhaler (refers to Flovent HFA 50 mcg, 125 mcg, and 250 mcg strengths available in Canada):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;5 years: &quot;Low&quot; dose: 100 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 100 to 200 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;200 to 500 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;500 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flovent Diskus (fluticasone propionate):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>\n        <b>\n          <i>US labeling: </i></b></i> Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to 11 years: Initial (patients with no prior inhaled corticosteroids): 50 mcg twice daily; may increase to maximum dose of 100 mcg twice daily in patients not adequately controlled after 2 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>\n        <b>\n          <i>Canadian labeling: </i></b></i> Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to &lt;16 years: Initial: 50 to 100 mcg twice daily; may increase up to 200 mcg twice daily after ~1 week of therapy in patients not adequately controlled</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Asthma guidelines:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program guidelines (NAEPP 2007) (administer in divided doses twice daily): Dry powder inhaler (refers to Flovent Diskus 50 mcg, 100 mcg, and 250 mcg strengths available in the US and Canada, and the 500 mcg strength available in Canada).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Low&quot; dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to 11 years: 100 to 200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;12 years: 100 to 300 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;Medium&quot; dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to 11 years: &gt;200 to 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;12 years: &gt;300 to 500 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&quot;High&quot; dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to 11 years: &gt;400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;12 years: &gt;500 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma guidelines (GINA 2017): Dry powder inhaler (refers to Flovent Diskus 50 mcg, 100 mcg, and 250 mcg strengths available in US and Canada, and the 500 mcg strength available in Canada).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 100 to 200 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;200 to 400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Eosinophilic esophagitis (off-label use):</b> Oral (off-label route):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: 176 to 880 mcg/day of aerosolized fluticasone swallowed (not inhaled). Dose may be divided into 2 doses (Konikoff 2006; Teitelbaum 2002). Doses as high as 880 mcg twice daily have been reported (Butz 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternatively, may dose according to age:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 4 years: 88 mcg of aerosolized fluticasone swallowed (not inhaled) twice daily (176 mcg/day) (Teitelbaum 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 10 years: 220 mcg of aerosolized fluticasone swallowed (not inhaled) twice daily (440 mcg/day) (Teitelbaum 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;11 years and Adolescents: 440 mcg of aerosolized fluticasone swallowed (not inhaled) twice daily (880 mcg/day) (Teitelbaum 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349627\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14306518\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arnuity Ellipta: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ArmonAir Respiclick, Flovent Diskus and Flovent HFA: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349628\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling (has not been studied); however, fluticasone is primarily cleared in the liver and plasma levels may be increased in patients with hepatic impairment. Arnuity Ellipta product labeling indicates that systemic exposure is increased up to 3-fold. Use with caution and closely monitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242572\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol, Inhalation, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flovent HFA: 44 mcg/actuation (10.6 g); 110 mcg/actuation (12 g); 220 mcg/actuation (12 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arnuity Ellipta: 100 mcg/actuation (14 ea, 30 ea); 200 mcg/actuation (14 ea, 30 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ArmonAir RespiClick 55: 55 mcg/actuation (1 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ArmonAir RespiClick 232: 232 mcg/actuation (1 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ArmonAir RespiClick 113: 113 mcg/actuation (1 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flovent Diskus: 50 mcg/blister (60 ea); 100 mcg/blister (28 ea, 60 ea); 250 mcg/blister (28 ea, 60 ea) [contains lactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349571\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005910\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Flovent HFA 10.6 g and 12 g canisters contain 120 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349666\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol, for oral inhalation, as propionate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent HFA:  50 mcg/inhalation (120 actuations); 125 mcg/inhalation (60 or 120 actuations); 250 mcg/inhalation (60 or 120 actuations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, for oral inhalation, as propionate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus: 50 mcg (60s) [contains lactose; prefilled blister pack]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus: 100 mcg (60s) [contains lactose; prefilled blister pack]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus: 250 mcg (60s) [contains lactose; prefilled blister pack]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus: 500 mcg (60s) [contains lactose; prefilled blister pack]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349630\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ArmonAir Respiclick: Administer the dose at approximately the same time every day. Does not require priming and do not use with a spacer or volume holding chamber. Following administration, rinse mouth with water after use (do not swallow). Do not wash or place any part of inhaler in water; if mouthpiece needs cleaning, gently wipe with a dry cloth or tissue. Discard inhaler 30 days after opening the foil pouch or when the counter reads &quot;0&quot; (whichever comes first).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Arnuity Ellipta: Administer the dose at the same time every day. Do not shake inhaler. When ready to use, open and prepare mouthpiece of the inhaler and slide the cover down to activate the first dose. Exhale fully (not into mouthpiece), take one deep breath through mouth without blocking air vents and hold breath for about 3 to 4 seconds. If the cover is opened and closed without inhaling the medicine, the dose will be lost. The lost dose will be held in the inhaler, but it will no longer be available to be inhaled. It is not possible to accidentally take a double dose or an extra dose in one inhalation. Following administration, rinse mouth with water after use (do not swallow). Routine cleaning of the inhaler is not required; may clean the mouthpiece if needed, using a dry tissue, before the cover is closed. Discard inhaler 6 weeks after opening the foil tray or when the counter reads &quot;0&quot; (device is not reusable).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flovent Diskus: Do not use with a spacer device. Do not exhale into Diskus. Do not wash or take apart. Use in horizontal position; do not tilt. Rinse mouth with water (without swallowing) after each use. Discard after 6 weeks (50 mcg diskus) or after 2 months (100 mcg and 250 mcg diskus) once removed from protective pouch or when the dose counter reads &quot;0&quot;, whichever comes first (device is not reusable).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metered dose inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flovent HFA: Shake container thoroughly for 5 seconds before each inhalation. Use inhaler on inspiration. Allow 30 seconds between inhalations. Rinse mouth with water (without swallowing) after each use. Inhaler must be primed before first use, when not used for 7 days, or if dropped. To prime the first time, release 4 sprays into air; shake well for 5 seconds before each spray and spray away from face. The counter should now read &quot;120&quot;. If dropped or not used for 7 days, prime by shaking well for 5 seconds and releasing a single test spray. Patient should contact pharmacy for refill when the dose counter reads &quot;020&quot;. Discard device when the dose counter reads &quot;000&quot;. Do not use &quot;float&quot; test to determine contents. Clean the inhaler at least once weekly; use a cotton swab dampened with water to clean circular opening of the metal canister and wipe the inside of the mouthpiece with a tissue dampened with water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (off-label route): For the treatment of eosinophilic esophagitis (off-label use), fluticasone is administered orally with a metered-dose inhaler without the use of a spacer. Administer as a spray into the mouth and swallow (do not inhale). Patients may not rinse, eat, or drink for 30 minutes after administration (Dellon 2013; Konikoff 2006; Teitelbaum 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242573\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ArmonAir Respiclick and Arnuity Ellipta: Maintenance treatment of asthma as prophylactic therapy in patients 12 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus and Flovent HFA: Maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b> A low-dose inhaled corticosteroid (<i>in addition to an as-needed short acting beta<sub>2</sub>-agonist</i>) is the initial preferred long-term control medication for children, adolescents, and adult patients with persistent asthma who are candidates for treatment according to a step-wise treatment approach (GINA 2017; NAEPP 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26979827\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic obstructive pulmonary disease (stable); Eosinophilic esophagitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349564\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Arnuity Ellipta may be confused with Anoro Ellipta, Breo Ellipta, and Incruse Ellipta; Ellipta is the inhaler delivery system trademark not a medication</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flovent may be confused with Flonase</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flovent [US, Canada] may be confused with Flogen brand name for naproxen [Mexico]; Flogene brand name for piroxicam [Brazil]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242567\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;16%), malaise (&le;16%), headache (2% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral candidiasis (&le;31%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;17%), musculoskeletal pain (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinus infection (&le;33%), sinusitis (&le;33%), upper respiratory tract infection (2% to 31%), throat irritation (&lt;1% to 22%), nasal congestion (&ge;3% to 16%), nasopharyngitis (8% to 13%), rhinitis (&lt;1% to 13%), bronchitis (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&le;1%), subarachnoid hemorrhage (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (10%), voice disorder (&le;9%), procedural pain (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (8%), pruritus (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (1% to 9%), viral gastrointestinal infection (3% to 5%), gastrointestinal distress (&le;4%), gastrointestinal pain (&le;4%), oropharyngeal candidiasis (3%), toothache (3%), viral gastroenteritis (3%), abdominal pain (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Malignant neoplasm of breast (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (4% to 7%), viral infection (&le;5%), abscess (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle injury (&le;5%), back pain (3%), herniated disk (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Viral respiratory infection (1% to 9%), cough (&le;9%), hoarseness (&le;9%), pharyngitis (3% to 6%), upper respiratory tract inflammation (&le;5%), oropharyngeal pain (3% to 4%), allergic rhinitis (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 7%), accidental injury (&le;5%), amputation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, agitation, allergic skin reaction, anaphylaxis, anxiety, aphonia, arthritis, behavioral changes, bronchospasm, bruise, burn, cataract, chest symptoms, chest tightness, Cushingoid appearance, decreased linear skeletal growth rate, dental caries, dental discoloration, dental discomfort, depression, diarrhea, dizziness, dyspepsia, dyspnea, ecchymoses, epistaxis, esophageal candidiasis, exacerbation of asthma, facial edema, gastrointestinal disease, hyperglycemia, hypersensitivity reaction (musculoskeletal), laryngitis, migraine, mood disorder, mouth disease, oropharyngeal edema, osteonecrosis, osteoporosis, paradoxical bronchospasm, pneumonia, restlessness, rhinorrhea, soft tissue injury, sore throat, urinary tract infection, weight gain, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349579\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluticasone or any component of the formulation; severe hypersensitivity to milk proteins or lactose (ArmonAir Respiclick, Arnuity Ellipta, Flovent Diskus); primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Flovent HFA and Flovent Diskus: Untreated fungal, bacterial or tubercular infections of the respiratory tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349580\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis in sensitive patients. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled corticosteroids due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Select surgical patients on long-term, high-dose, inhaled corticosteroid (ICS), should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs, stop steroid and treat with a fast-acting bronchodilator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Immediate hypersensitivity reactions (eg, angioedema, bronchospasm, hypotension, rash, urticaria), including anaphylaxis, may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; active or quiescent tuberculosis infections of the respiratory tract; or viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox and measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered. With oral inhalation, local yeast infections (eg, oropharyngeal candidiasis) may occur; patient should rinse mouth with water and spit after each use to reduce incidence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while continuing fluticasone therapy. Patients should be instructed to rinse mouth with water without swallowing after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Short-acting beta<sub>2</sub>-agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention. Impairment of liver function may lead to accumulation of fluticasone in plasma. Monitor patients for corticosteroid related adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ArmonAir Respiclick, Arnuity Ellipta, and Flovent Diskus: May contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of systemic corticosteroids: Withdraw systemic corticosteroid therapy with gradual tapering of dose; consider reducing the daily prednisone dose by 2.5 to 5 mg on a weekly basis beginning after at least 1 week of inhalation therapy. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfer to oral inhaler: When transferring to oral inhaler, previously suppressed allergic conditions (arthritis, rhinitis, conjunctivitis, eczema, eosinophilic conditions) may be unmasked.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349607\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349606\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9136&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation). Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended.  Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution.  Monitor patients using such a combination more closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Fluticasone (Oral Inhalation).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349575\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy (Battista 2016). Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG 2008; GINA 2016; Namazy 2016). Pregnant females adequately controlled on fluticasone for asthma may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females may be preferred (Namazy 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349578\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sufficient quantities of fluticasone are absorbed following inhalation to produce detectable amounts in breast milk. Systemic corticosteroids are present in human milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The use of inhaled corticosteroids is not considered a contraindication to breastfeeding (ACOG 2008). Females with asthma should be encouraged to breastfeed (GINA 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349629\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">ArmonAir Respiclick, Arnuity Ellipta and Flovent Diskus may contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242570\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth (adolescents and children via stadiometry); signs/symptoms of HPA axis suppression/adrenal insufficiency; signs/symptoms of oral candidiasis; possible eosinophilic conditions (including Churg-Strauss syndrome); FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; asthma symptoms; bone mineral density; hepatic impairment; glaucoma/cataracts</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242564\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity. The effectiveness of inhaled fluticasone is due to its direct local effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349615\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Maximal benefit may take 1 to 2 weeks or longer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Absorbed systemically primarily via lungs (Flovent Diskus: ~18%); minimal GI absorption (&lt;1%) due to presystemic metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 4.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 to 17&beta;-carboxylic acid (negligible activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral inhalation: 13.9%; Flovent Diskus: ~8%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~8 hours; Oral inhalation (plasma elimination phase following repeat dosing): 24 hours (ArmonAir Respiclick: ~11.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (as parent drug and metabolites); urine (&lt;5% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349664\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Flovent HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">44 mcg/ACT (10.6 g): $218.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">110 mcg/ACT (12 g): $291.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mcg/ACT (12 g): $453.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ArmonAir RespiClick 113 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">113 mcg/ACT (1): $271.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ArmonAir RespiClick 232 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">232 mcg/ACT (1): $271.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ArmonAir RespiClick 55 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55 mcg/ACT (1): $203.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Arnuity Ellipta Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/ACT (14): $94.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/ACT (14): $126.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Flovent Diskus Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/blister (60): $206.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/blister (28): $126.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg/blister (28): $170.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707662\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allegro (IL);</li>\n      <li>Allevisone (TW);</li>\n      <li>Arnuity (JP);</li>\n      <li>Arnuity Ellipta (SG);</li>\n      <li>Atemur Mite (DE);</li>\n      <li>Axotide (CH);</li>\n      <li>Dalman AQ (HK);</li>\n      <li>Flixotaide (PT);</li>\n      <li>Flixotide (AE, AR, AT, BE, BG, BH, BR, CL, CN, CR, CY, CZ, DK, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KR, KW, LB, LT, LU, LV, LY, MT, MY, NI, NL, NZ, OM, PA, PE, PH, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TT, TW, UY, VE, VN, YE, ZW);</li>\n      <li>Flixotide Inhaler (AU);</li>\n      <li>Flixotide Nebules (AU);</li>\n      <li>Flixovate (FR);</li>\n      <li>Flohale (AE, ZW);</li>\n      <li>Flomist (MY);</li>\n      <li>Flutaide (PT);</li>\n      <li>Flutica (DE);</li>\n      <li>Flutico (BD);</li>\n      <li>Flutide (DE, SE);</li>\n      <li>Flutimar HFA (CO);</li>\n      <li>Flutitrim (SG);</li>\n      <li>Flutivate (BR, DE);</li>\n      <li>Futisone (TW);</li>\n      <li>Lutisone (HK);</li>\n      <li>Medicort (ID);</li>\n      <li>Meseca (VN);</li>\n      <li>Nasofan (HK);</li>\n      <li>Rheoran F (LK);</li>\n      <li>Zoflut (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. <i>Clin Gastroenterol Hepatol</i>. 2012;10(7):742-749.e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/22475741/pubmed\" target=\"_blank\" id=\"22475741\">22475741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ArmonAir Respiclick (fluticasone propionate inhalation powder) [prescribing information]. Frazer, PA: Teva Respiratory, LLC; January 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/22475741/pubmed\" target=\"_blank\" id=\"22475741\">22475741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnuity Ellipta (fluticasone furoate inhalation powder) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Battista MC, Boutin M, Venne P, et al. Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. <i>Bioanalysis</i>. 2016 Jun 28. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/27349687/pubmed\" target=\"_blank\" id=\"27349687\">27349687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butz BK, Wen T, Gleich GJ, Furuta GT, at al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. <i>Gastroenterology</i>. 2014;147(2):324-333.e5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/24768678/pubmed\" target=\"_blank\" id=\"24768678\">24768678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chuang MY, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): A systematic review and meta-analysis. <i>Clin Transl Gastroenterol</i>. 2015;6:e82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/25809314/pubmed\" target=\"_blank\" id=\"25809314\">25809314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flovent Diskus (fluticasone propionate inhalation powder) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flovent Diskus (fluticasone propionate inhalation powder) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flovent HFA (fluticasone propionate inhalation aerosol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flovent HFA (fluticasone propionate inhalation aerosol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Strategy for Diagnosis Management of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014. Available from: http://www.goldcopd.org/.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. <i>Gastroenterology</i>. 2006;131(5):1381-1391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/17101314/pubmed\" target=\"_blank\" id=\"17101314\">17101314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo; <i>Can Respir J</i>, 2010, 17(1):15-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/20186367/pubmed\" target=\"_blank\" id=\"20186367\">20186367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murali AR, Gupta A, Attar BM, Ravi V, Koduru P. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo controlled randomized clinical trials [published online ahead of print December 23, 2015]. <i>J Gastroenterol Hepatol</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/26699695/pubmed\" target=\"_blank\" id=\"26699695\">26699695</a>]</span><span class=\"doi\">10.1111/jgh.13281</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/27012010/pubmed\" target=\"_blank\" id=\"27012010\">27012010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, &quot;Guidelines for the Diagnosis and Management of Asthma,&quot; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teitelbaum JE, Fox VL, Twarog FJ, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. <i>Gastroenterology</i>. 2002;122(5):1216-1225.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/11984507/pubmed\" target=\"_blank\" id=\"11984507\">11984507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd GR, Acerini CL, Buck JJ, et al, &quot;Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate,&quot; <i>Eur Respir J</i>, 2002, 19(6):1207-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/12108877/pubmed\" target=\"_blank\" id=\"12108877\">12108877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd GR, Acerini CL, Ross-Russell R, et al, &quot;Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom,&quot; <i>Arch Dis Child</i>, 2002, 87(6):457-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-drug-information/abstract-text/12456538/pubmed\" target=\"_blank\" id=\"12456538\">12456538</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9136 Version 190.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9349568\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9349569\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9349572\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9349626\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9349625\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9349627\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14306518\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9349628\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242572\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9349571\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005910\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F9349666\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9349630\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F242573\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26979827\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9349564\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F242567\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9349579\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9349580\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9349607\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9349606\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9349575\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9349578\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9349629\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F242570\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F242564\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9349615\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9349664\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707662\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluticasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Fluticasone (oral inhalation): Patient drug information \t</a></li><li><a href=\"topic.htm?path=fluticasone-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluticasone (oral inhalation): Pediatric drug information</a></li></ul></div></div>","javascript":null}